First-in-human, phase 1 trial of datopotamab deruxtecan for advanced non-small cell lung cancer
Prof. Toshio Shimizu
More effective and tolerable options are needed for the treatment of advanced non-small cell lung cancer. The first-in-human, phase 1 TROPION-PanTumor01 trial, in Japan and the USA, evaluated the TROP2-directed antibody-drug conjugate dapotomab deruxtecan (Dato-DXd) for heavily pretreated locally advanced or metastatic NSCLC. Dato-DXd showed promising antitumor activity and a manageable safety profile. At the recommended dose for further development, the objective response rate was 26%, the median duration of response was 10.5 months, the median progression-free survival was 6.9 months, and the median overall survival was 11.4 months. Responses were seen regardless of TROP2 expression level.
